Search research articles
Contact Us
Filters
Showing results (221-230 of 383) with videos related to
Page
of 39
Sort By:
Blood
|
August 4, 2010
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)
Timothy P Hughes, Andreas Hochhaus, Susan Branford, et al.
American Journal of Hematology
|
September 16, 2024
White blood cell count levels are associated with inflammatory response and constitute independent outcome predictors in adult patients with acute myeloid leukemia aged <60 years
Michael Ozga, Deedra Nicolet, Krzysztof Mrózek, et al.
Cancer
|
March 11, 2003
Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311
Ted P Szatrowski, Richard K Dodge, Carol Reynolds, et al.
Journal of Hematology & Oncology
|
January 7, 2018
A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia
Amy Y Wang, Howard Weiner, Margaret Green, et al.
Haematologica
|
May 5, 2022
Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia
Kathryn E Flynn, Ehab Atallah, Li Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 30, 2004
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621
Jonathan E Kolitz, Stephen L George, Richard K Dodge, et al.
Blood Advances
|
July 15, 2022
Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia
Lori Muffly, Jun Yin, Sawyer Jacobson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
August 8, 2016
Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy
Katarzyna Rojek, Eric Nickels, Barbara Neistadt, et al.
Leukemia & Lymphoma
|
September 15, 2011
High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML)
Sarah M Larson, Nicholas P Campbell, Dezheng Huo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 16, 2004
Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461
Guido Marcucci, Krzysztof Mrózek, Amy S Ruppert, et al.
Page
of 39
Search research articles
Search
Showing results (221-230 of 383) with videos related to
Sort By:
Page
of 39
Blood
|
August 4, 2010
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)
Timothy P Hughes, Andreas Hochhaus, Susan Branford, et al.
American Journal of Hematology
|
September 16, 2024
White blood cell count levels are associated with inflammatory response and constitute independent outcome predictors in adult patients with acute myeloid leukemia aged <60 years
Michael Ozga, Deedra Nicolet, Krzysztof Mrózek, et al.
Cancer
|
March 11, 2003
Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311
Ted P Szatrowski, Richard K Dodge, Carol Reynolds, et al.
Journal of Hematology & Oncology
|
January 7, 2018
A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia
Amy Y Wang, Howard Weiner, Margaret Green, et al.
Haematologica
|
May 5, 2022
Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia
Kathryn E Flynn, Ehab Atallah, Li Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 30, 2004
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621
Jonathan E Kolitz, Stephen L George, Richard K Dodge, et al.
Blood Advances
|
July 15, 2022
Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia
Lori Muffly, Jun Yin, Sawyer Jacobson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
August 8, 2016
Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy
Katarzyna Rojek, Eric Nickels, Barbara Neistadt, et al.
Leukemia & Lymphoma
|
September 15, 2011
High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML)
Sarah M Larson, Nicholas P Campbell, Dezheng Huo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 16, 2004
Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461
Guido Marcucci, Krzysztof Mrózek, Amy S Ruppert, et al.
Page
of 39